2.89% Dividend Yield, 54 Years of Dividend Hikes – A Medical Tech Leader In Syringes, Diagnostics, And Infusion
This company makes the syringes, catheters, and diagnostic tools that hospitals can’t live without, powering everything from routine blood draws to complex surgeries across 190 countries. It’s carved out dominant market share through innovation and scale, turning essential consumables into a steady revenue stream while its pipeline of connected devices keeps margins climbing. That combo has let it weather pandemics, recessions, and supply shocks with unwavering dividend commitment.
Becton, Dickinson and Company (BDX)
Financial Score: 96 / 99
Quick Tip
To keep your portfolio strong, stay on top of the financials for each company you hold. Solid companies mean better returns, so be sure to check in on their quarterly and annual numbers.Interesting stocks usually score 80+ on the Financial Scale, with top players hitting 90+. If that score dips below 80, it might be a good time to consider cutting ties before things take a turn.Becton, Dickinson and Company (BDX) is a global medical technology leader focused on medication management, diagnostics, and surgical instruments, serving healthcare providers in over 190 countries. Headquartered in Franklin Lakes, New Jersey, it operates three main segments: BD Medical (infusion, syringes), BD Life Sciences (diagnostics), and BD Interventional (surgery, vascular access), with a portfolio of 50,000+ products. Founded in 1897 as a glass syringe maker, it pioneered disposable needles and has grown to $20+ billion revenue via acquisitions like C.R. Bard.
Dividend dynasty: aristocrat with medtech muscle
BDX shells out $4.20 per share annually, hitting a 2.89% yield and 68.52% payout ratio—right in the sweet spot for growth without strain. The jaw‑dropping 54 years of consecutive dividend growth and +30.00% five‑year dividend growth prove it’s not just surviving; it’s thriving through every cycle. Stability comes from recurring consumable sales (think syringes used daily worldwide), $1.5+ billion R&D spend fueling innovations, and free cash flow that covers payouts 1.5x. You sleep easy knowing hospitals keep buying, no matter the economy—this is dividend royalty.
Q1 Fiscal 2026: revenues up 1.6%, adjusted EPS beats
For Q1 fiscal 2026 (ended Dec. 31, 2025), reported February 9, 2026, BD reported revenues of $5.25 billion, up 1.6% reported (0.4% FX-neutral), beating estimates by 2%. GAAP diluted EPS was $1.34 (up 28.8%), adjusted diluted EPS $2.91 (down 15.2% due to taxes but beat estimates by $0.09). New BD (post-separation) revenues grew 2.5% FXN, with adjusted gross margin at 53.4%.
Momentum builders: New BD growth, Waters spin‑off cash, product launches
New BD delivered 2.5% FX-neutral revenue growth in Q1 2026, with mid‑single digits across 90% of portfolio including PureWick, pharmacy automation, and biologic delivery. The Life Sciences/Waters reverse Morris Trust closed early, unlocking $4 billion cash split between $2 billion debt paydown and $2 billion buybacks. FY26 guidance affirms low single‑digit revenue growth for New BD and adjusted EPS $12.35–$12.65 (up ~6% midpoint), plus recent launches like all‑in‑one central venous catheter.
Fun Fact – Invented the modern hypodermic needle
In 1954, BD introduced the first disposable plastic syringe, slashing infection risks and sparking the shift from glass to single‑use medtech worldwide.
Final Take – A medtech king with separation upside
BDX cranks a 2.89% yield from $4.20 annual dividends, 68.52% payout, 54 years of hikes, and +30% five‑year growth, fueled by essential consumables and innovation. Q1 FY26 (Feb. 9, 2026 report) posted $5.25 billion revenues (up 1.6%, beat by 2%), $1.34 GAAP EPS (up 29%), $2.91 adjusted EPS (beat estimates). Financial Score: 96. That’s truly reliable elite—above 90 puts it in the top tier; risks like tariffs or China vaccines fade against hospital must‑haves, Waters cash flood, and 2.5% New BD growth, making it a set‑it‑and‑forget‑it powerhouse.
Someone’s sitting in the shade today because someone planted a tree a long time ago. ― Warren Buffett.
Learn the MaxDividends Way
Start Here
🔑 Explore the Premium Hub (exclusive — upgrade to unlock)
Guides & Step-by-Step
Deep Insights
📖 I ❤️ Dividends: Why I Believe Dividend Investing Is the Best Strategy | E-Book
How Effective is the MaxDividends Strategy for Building Growing Passive Income
Help & Support
Got a question about dividends? Ask Max, your AI Dividend Assistant!
Didn’t get the answer you need? Reach out: max@maxdividends.app or team@maxdividends.app — we’ll help you out.